A patient-focused approach to thrombolytic use in the management of catheter malfunction

Seminars in Dialysis

Volumn 19, Issue 5, 2006, Pages 381-390

  Lok, Charmaine E ^a   Thomas, Alison ^b   Vercaigne, Lavern ^c  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC AGENT;

ALGORITHM; CENTRAL VENOUS CATHETERIZATION; FIBRINOLYTIC THERAPY; HUMAN; METHODOLOGY; RENAL REPLACEMENT THERAPY; REVIEW; VEIN THROMBOSIS;

ALGORITHMS; CATHETERIZATION, CENTRAL VENOUS; FIBRINOLYTIC AGENTS; HUMANS; RENAL DIALYSIS; THROMBOLYTIC THERAPY; VENOUS THROMBOSIS;

EID: 33748714020     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2006.00151.x-i1     Document Type: Review

References (29)

1. NKF-K/DOQI Clinical Practice Guidelines for Vascular Access: update 2000. Am J Kidney Dis 37(suppl 1):S137-S181, 2001
2. Ethier JH, Lindsay RM, Barre PE, Kappel JE, Carlisle EJ, Common A: Clinical practice guidelines for vascular access. Canadian Society of Nephrology. J Am Soc Nephrol 10:S297-S305, 1999
3. Astor BC, Eustace JA, Powe NR, Klag MJ, Fink NE, Coresh J, CHOICE Study: Type of vascular access and survival among incident hemodialysis patients: the Choices for Healthy Outcomes in Caring for ESRD (CHOICE) Study. J Am Soc Nephrol 16:1449-1455, 2005
4. Besarab A, Brouwer D: Aligning hemodialysis treatment practices with the national kidney foundation's K/DOQI vascular access guidelines. Dial Transplant 33:694-702, 2004
5. Mendelssohn DC, Ethier J, Elder SJ, Saran R, Port FK, Pisoni RL: Haemodialysis vascular access problems in Canada: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS II). Nephrol Dial Transplant 21:721-728, 2005
6. U.S. Renal Data System: USRDS 2004 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2004
7. Lok CE, Oliver MJ, Rothwell DM, Hux JE: The growing volume of diabetes-related dialysis: a population based study. Nephrol Dial Transplant 19:3098-3103, 2004
8. Clase CM, Crowther MA, Ingram AJ, Cina CS: Thrombolysis for restoration of patency to haemodialysis central venous catheters: a systematic review. J Thromb Thrombolysis 11:127-136, 2001
9. Spry LA, Miller G: Low-dose tPA for hemodialysis catheter clearance. Dial Transplant 30:10-1254, 2001
10. Meers C, Toffelmire EB: Tissue plasminogen activator (t-PA) efficacy in the restoration of hemodialysis catheter function. CANNT J 9:25-28, 1999
11. MacRae JMLG, Djurdjev O, Shalansky S, Werb R, Levin A, Kiaii M: Short and long alteplase dwells in dysfunctional hemodialysis catheters. Hemodial Int 9:189-195, 2005
12. O'Mara NB, Ali S, Bivens K, Shermann RA, Kapoian T: Efficacy of tissue plasminogen activator for thrombolysis in central venous dialysis catheters. Hemodial Int 7:130-134, 2003
13. Nguyen TV, Dikun M: Establishing an alteplase dosing protocol for hemodialysis-catheter thrombosis. Am J Health Syst Pharm 61:1922-1924, 2004
14. Castner D: The efficacy of reteplase in the treatment of thrombosed hemodialysis venous catheters. Nephrol Nurs J 28:403-404, 407-410, 2001
15. Falk A, Samson W, Uribarri J, Vassalotti JA: Efficacy of reteplase in poorly functioning hemodialysis catheters. Clin Nephrol 61:47-53, 2004
16. Hyman G, England M, Kibede S, Lee P, Willets G: The efficacy and safety of reteplase for thrombolysis of hemodialysis catheters at a community and academic regional medical center. Nephrol Clin Pract 96:c39-c42, 2004
17. Paulsen D, Reisoether A, Aasen M, Fauchald P: Use of tissue plasminogen activator for reopening of clotted dialysis catheters. Nephron 64:468-470, 1993
18. Daeihagh P, Jordan J, Chen J, Rocco M: Efficacy of tissue plasminogen activator administration on patency of hemodialysis access catheters. Am J Kidney Dis 36:75-79, 2000
19. Little MA, Walshe JJ: A longitudinal study of the repeated use of alteplase as therapy for tunneled hemodialysis catheter dysfunction. Am J Kidney Dis 39:86-91, 2002
20. Hilleman DE, Dunlay RW, Packard KA: Reteplase for dysfunctional hemodialysis catheter clearance. Pharmacotherapy 23:137-141, 2003
21. Twardowski Z: High-dose intradialytic urokinase to restore the patency of permanent central vein hemodialysis catheters. Am J Kidney Dis 31:841-847, 1998
22. Savader SJ, Ehrman KO, Porter DJ, Haikal LC, Oteham AC: Treatment of hemodialysis catheter-associated fibrin sheaths by rt-PA infusion: critical analysis of 124 procedures. J Vasc Interv Radiol 12:711-715, 2001
23. Dowling K, Sansivero G, Stainken B, Siskin G, Dolen E, Ahn J, Mitchell N: The use of tissue plasminogen activator infusion to re-establish function of tunneled hemodialysis catheters. Nephrol Nurs J 31:99-200, 2004
24. Week SCS, Hiraoka-Sutow M, Patapoff T, Semba CP: Alteplase as a catheter locking solution: in vitro evaluation of biochemical stability and antimicrobial properties. J Vasc Interv Radial 16:379-383, 2005
25. Hamond J, Shalansky K, Jastrzebski J: Efficacy of low-dose alteplase for treatment of hemodialysis catheter occlusions. J Vasc Access 6:76-82, 2005
26. Eyrich H, Walton T, Macon EJ, Howe A: Alteplase versus urokinase in restoring blood flow in hemodialysis-catheter thrombosis. Am J Health Syst Pharm 59:1437-1440, 2002
27. Zacharias JM, Weatherston CP, Spewak CR, Vercaigne LM: Alteplase versus urokinase for occluded hemodialysis catheters. Ann Pharmacother 37:27-33, 2003
28. NKF-K/DOQI Clinical Practice Guidelines for Hemodialysis Adequacy: update 2000. Am J Kidney Dis 37:S7-S64, 2001
29. Deziel C, Hirsch DJ, Hoult P, Levin A, Sohi P, Taub KJ, Watson D: Clinical practice guidelines for the delivery of hemodialysis. Canadian Society of Nephrology. J Am Soc Nephrol 10:S306-S310, 1999